Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019.

Aultman, Kathi; Cirucci, Christina A; Harrison, Donna J; Beran, Benjamin D; Lockwood, Michael D; Seiler, Sigmund

Aultman, Kathi; Cirucci, Christina A; Harrison, Donna J; Beran, Benjamin D; Lockwood, Michael D; Seiler, Sigmund.

Afiliación

Aultman K; Associate Scholar with the Charlotte Lozier Institute.
Harrison DJ; Executive Director, American Association of Pro-Life Obstetricians and Gynecologists, PO Box 395 Eau Claire, Michigan 49111-0395. Ph 202 230-0997. donna@aaplog.org.
Beran BD; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI.
Lockwood MD; Department of Osteopathic Manipulative Medicine, Liberty University College of Osteopathic Medicine.
Seiler S; Associate Professor of Family Medicine, Liberty University College of Osteopathic Medicine.

Issues Law Med ; 36(1): 3-26, 2021.

Article en En | MEDLINE | ID: mdl-33939340

Asunto(s)

Abortivos; Mifepristona/efectos adversos; Abortivos/efectos adversos; Abortivos Esteroideos/efectos adversos; Aborto Inducido/efectos adversos; COVID-19; Femenino; Humanos; Misoprostol; Pandemias; Embarazo; SARS-CoV-2

Palabras clave

Abortifacient; Abortion Pill; Adverse Event Reports; Adverse Events; DIY Abortion; Drug Safety; Emergency Medicine; FAERS; FDA; Medical Abortion; Medical Abortion Complications; Mifeprex; Mifepristone; Misoprostol; No touch abortion; Post-marketing Surveillance; REMS; RU-486; Risk Evaluation Mitigation Strategy; Self-Administered Abortion

Buscar en Google

Imprimir

XML

PubMed Links

Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Abortivos / Mifepristona Tipo de estudio: Prognostic_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Issues Law Med Asunto de la revista: JURISPRUDENCIA Año: 2021 Tipo del documento: Article

Buscar en Google

Imprimir

XML

PubMed Links